Clinical trials: Cutaneous Squamous Cell Carcinoma (CSCC)
Advanced Cutaneous Squamous Cell Carcinoma
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
- Trial name
- NCT02760498
- Testing
- cemiplimab
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 432 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) pembrolizumab (+) berahyaluronidase alfa in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma…
- Trial name
- NCT06041802
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 18 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Patient reported outcomes in patients with high-risk cutaneous squamous cell carcinoma in the head-neck region are an important part of the complex care for these patients.
- Conditions
- Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinomas, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05482880
- Testing
- Regular care with additionally administration of questionnaires
- Where
- 2 sites in Netherlands
- Volunteers
- 78 people
- Sponsor
- Maastricht University Medical Center
Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
The purpose of this first in human and proof of concept study is to characterize the safety, tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ (SCCis) to enable further clinical…
- Trial name
- NCT03333694
- Testing
- Cutaneous Cream application
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery.
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
- Trial name
- NCT06664151
- Testing
- Fluzone Trivalent
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed…
- Trial name
- NCT04925713
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- TuHURA Biosciences, Inc.
Cutaneous Squamous Cell Carcinoma (CSCC)
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, it exhibits a high tumor mutational burden and is more common in immunocompromised patients, which aimed to explore the impact of…
- Trial name
- NGF-GRACE (NCT07064330)
- Testing
- Cemiplimab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Cutaneous Squamous Cell Carcinoma (CSCC)
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
The goal of this clinical trial is to evaluate if short-course radiation therapy (SCRT) can effectively treat high-risk cutaneous squamous cell carcinoma (cSCC) and if active surveillance is a safe alternative to radiation for…
- Trial name
- MOHSAHRTSS (NCT06998342)
- Testing
- Short course radiation, Active Surveillance
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT04799054
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Cutaneous Squamous Cell Carcinoma (CSCC)
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
The goal of this clinical trial is to evaluate a strategy integrating adjuvant radiation therapy versus strategy based on monitoring in the treatment of carcinomas spinocellular with high risk of recurrence (SCC).
- Trial name
- SPINO-RT (NCT06692556)
- Testing
- Adjuvant radiotherapy
- Where
- 28 sites in France
- Volunteers
- 266 people
- Sponsor
- Centre Leon Berard
Cutaneous Squamous Cell Carcinoma (CSCC)
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells.
- Trial name
- NCT06585410
- Testing
- Cemiplimab, Standard of care
- Where
- 53 sites in United States, Australia
- Volunteers
- 369 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant, Solid Tumor, Solid Tumor Cancer
- Trial name
- NCT07100925
- Testing
- tolododekin alfa
- Sponsor
- Ankyra Therapeutics, Inc
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body.
- Trial name
- NCT03944941
- Testing
- Avelumab, Cetuximab
- Where
- 428 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
This study is researching an investigational drug called REGN2810, also known as cemiplimab, and when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or…
- Trial name
- NCT06384820
- Testing
- cemiplimab, fianlimab
- Sponsor
- Regeneron Pharmaceuticals
SCC - Squamous Cell Carcinoma of Skin
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
- Trial name
- NCT04812535
- Testing
- Vilobelimab, Vilobelimab + pembrolizumab combination therapy
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- InflaRx GmbH
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
This phase II trial studies how well pembrolizumab works in treating patients with orbital (eye socket) and/or periorbital (surrounding the eye socket) cutaneous squamous cell cancer (cSCC) that has spread to nearby tissue or…
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT06580054
- Testing
- Computed Tomography, Digital Photography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to…
- Trial name
- NCT04242173
- Testing
- Cemiplimab-Rwlc
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cutaneous Squamous Cell Carcinoma (CSCC)
Usefulness of Post-Operative Radiotherapy in High-grade Cutaneous Squamous Cell Carcinoma: an Observational Study
Post-operative radiotherapy (PORT) is currently considered as the second most important therapy to treat high-grade cutaneous squamous cell carcinoma.
- Trial name
- PORTSCC (NCT06879964)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia